MINE-ESHAP联合方案治疗难治或复发性非霍奇金淋巴瘤28例  

Effect of MINE-ESHAP regimen in treatment of refractory or relapsed non-Hodgkin lymphoma

作　　者：冯国安[1] 邢正云[1] 

机构地区：[1]江苏省大丰市人民医院血液肿瘤科,224100

出　　处：《白血病．淋巴瘤》2010年第6期363-364,共2页Journal of Leukemia & Lymphoma

摘　　要：目的 探讨MINE-ESHAP联合方案治疗难治性或复发性非霍奇金淋巴瘤（NHL）的疗效.方法 采用MINE-ESHAP联合方案治疗难治性或复发性NHL 28例.结果 28例患者中,CR 11例（39.3%）,PR 6例（21.4%）,SD 5例（17.9%）,进展或恶化5例（17.9%）,中位生存时间28.5个月.1例死于骨髓抑制期感染（3.6%）.不良反应主要为消化道症状和骨髓抑制.结论 MINE-ESHAP方案对部分难治性或复发性NHL患者有效,不良反应可以耐受,可用于对其他化疗方案无效的难治性或复发性NHL.Objective To evaluate the efficacy of MINE-ESHAP regimen in treatment of refractory and relapsed non-Hodgkin lymphoma （NHL）. Methods Twenty-eight patients with refractory and relapsed NHL were treated with MINE-ESHAP regimen. Results The rate of complete remission was 39.3 %（11/28）,of partial remission 21.4 %（6/28）,of stable disease 17.9 %（5/28）,and of progression 17.94 %（5/28）. The midsurvival time was 28.5 months. One patient died of infection during marrow restrain period. The main toxicities included gastrointestinal symptoms and myelosuppression. Conclusion MINE-ESHAP regimen is sate and could be employed in treatment of the patients with refractory and relapsed NHL.

关 键 词：淋巴瘤 非霍奇金 抗肿瘤联合化疗方案 疗效 

分 类 号：R733.1[医药卫生—肿瘤]